Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance Study of BIIB122 in Healthy Males
NCT05119790Phase 1Completed
- Sponsor
- Biogen
- Start
- Aug 2021
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BIIB122 in Parkinson's disease (PD), sponsored by Biogen. Primary endpoints: Mass balance (total recovery) at 43 days, Percentage of radioactivity recovered in urine at 43 days and 8 more. Started Aug 2021; status: completed.
02
Drugs
BIIB122
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT05119790.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05119790.